# EDGAR Filing Document

**Accession Number:** 0001516551
**File Stem:** 0001628280-25-051031
**Filing Date:** 2025-11
**Character Count:** 105276
**Document Hash:** 0d860ab7b7252ff8fc9c16ee78e705fe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-051031.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001628280-25-051031

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 59

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Skye Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001516551
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 450692882
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42009
- **FILM NUMBER:** 251466247

**BUSINESS ADDRESS:**
- **STREET 1:** 11250 EL CAMINO REAL, SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 410-0266

**MAIL ADDRESS:**
- **STREET 1:** 11250 EL CAMINO REAL, SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Emerald Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20190325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nemus Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20141030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LOAD GUARD LOGISTICS, INC.
- **DATE OF NAME CHANGE:** 20121107

?xml version='1.0' encoding='ASCII'? skye-20250930

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒&nbsp;&nbsp;&nbsp;&nbsp;**QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2025

**or**

☐&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: **<u>000-55136</u>**

**Skye Bioscience, Inc.**

_____________________________________________________________

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **45-0692882** |
| (State or other jurisdiction<br>of incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**<u>11250 El Camino Real, Suite 100, San Diego, CA 92130</u>**

(Address of principal executive offices) (Zip Code)

**<u>(858) 410-0266</u>**

(Registrant's telephone number, including area code)

**__________________________N/A_______________________________**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange<br>on which registered |
| Common Stock, par value $0.001 | SKYE | Nasdaq Global Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of November 7, 2025, there were 32,057,461 shares of the registrant's common stock, $0.001 par value, issued and outstanding.

------

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **<u>[PART I - FINANCIAL INFORMATION](#i422a8f735e3340ef90fc826b443975cf_10)</u>** | **<u>[PART I - FINANCIAL INFORMATION](#i422a8f735e3340ef90fc826b443975cf_10)</u>** | **<u>[PART I - FINANCIAL INFORMATION](#i422a8f735e3340ef90fc826b443975cf_10)</u>** |
| <u>[Item 1.](#i422a8f735e3340ef90fc826b443975cf_13)</u> | <u>[Financial Statements:](#i422a8f735e3340ef90fc826b443975cf_13)</u> | [4](#i422a8f735e3340ef90fc826b443975cf_13) |
|  | <u>[Condensed Consolidated Balance Sheets as of](#i422a8f735e3340ef90fc826b443975cf_16)September 30, 2025[(Unaudited) and](#i422a8f735e3340ef90fc826b443975cf_16)December 31, 2024</u> | [4](#i422a8f735e3340ef90fc826b443975cf_13) |
|  | <u>[Condensed Consolidated Statements of Operations for the](#i422a8f735e3340ef90fc826b443975cf_22)Three and Nine Months Ended September 30, 2025 and 2024 [(Unaudited)](#i422a8f735e3340ef90fc826b443975cf_22)</u> | [6](#i422a8f735e3340ef90fc826b443975cf_22) |
|  | <u>[Condensed Consolidated Statements of Cash Flows for the](#i422a8f735e3340ef90fc826b443975cf_28) Nine Months Ended September 30, 2025 and 2024 (Unaudited)</u> | [7](#i422a8f735e3340ef90fc826b443975cf_25) |
|  | <u>[Condensed Consolidated Statements of Stockholders' Equity for the](#i422a8f735e3340ef90fc826b443975cf_31)Three and Nine Months Ended September 30, 2025 and2024[(Unaudited)](#i422a8f735e3340ef90fc826b443975cf_31)</u> | [8](#i422a8f735e3340ef90fc826b443975cf_31) |
|  | <u>[Notes to the Unaudited Condensed Consolidated Financial Statements](#i422a8f735e3340ef90fc826b443975cf_37)</u> | [10](#i422a8f735e3340ef90fc826b443975cf_37) |
| <u>[Item 2.](#i422a8f735e3340ef90fc826b443975cf_67)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i422a8f735e3340ef90fc826b443975cf_67)</u> | [18](#i422a8f735e3340ef90fc826b443975cf_67) |
| <u>[Item 3.](#i422a8f735e3340ef90fc826b443975cf_91)</u> | <u>[Quantitative and Qualitative Disclosures about Market Risk](#i422a8f735e3340ef90fc826b443975cf_91)</u> | [26](#i422a8f735e3340ef90fc826b443975cf_91) |
| <u>[Item 4.](#i422a8f735e3340ef90fc826b443975cf_94)</u> | <u>[Controls and Procedures](#i422a8f735e3340ef90fc826b443975cf_94)</u> | [26](#i422a8f735e3340ef90fc826b443975cf_94) |
| **<u>[PART II - OTHER INFORMATION](#i422a8f735e3340ef90fc826b443975cf_97)</u>** | **<u>[PART II - OTHER INFORMATION](#i422a8f735e3340ef90fc826b443975cf_97)</u>** | **<u>[PART II - OTHER INFORMATION](#i422a8f735e3340ef90fc826b443975cf_97)</u>** |
| <u>[Item 1.](#i422a8f735e3340ef90fc826b443975cf_100)</u> | <u>[Legal Proceedings](#i422a8f735e3340ef90fc826b443975cf_100)</u> | [27](#i422a8f735e3340ef90fc826b443975cf_100) |
| <u>[Item 1A.](#i422a8f735e3340ef90fc826b443975cf_103)</u> | <u>[Risk Factors](#i422a8f735e3340ef90fc826b443975cf_103)</u> | [27](#i422a8f735e3340ef90fc826b443975cf_103) |
| <u>[Item 2.](#i422a8f735e3340ef90fc826b443975cf_106)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i422a8f735e3340ef90fc826b443975cf_106)</u> | [27](#i422a8f735e3340ef90fc826b443975cf_106) |
| <u>[Item 3.](#i422a8f735e3340ef90fc826b443975cf_109)</u> | <u>[Defaults Upon Senior Securities](#i422a8f735e3340ef90fc826b443975cf_109)</u> | [27](#i422a8f735e3340ef90fc826b443975cf_109) |
| <u>[Item 4.](#i422a8f735e3340ef90fc826b443975cf_112)</u> | <u>[Mine Safety Disclosures](#i422a8f735e3340ef90fc826b443975cf_112)</u> | [27](#i422a8f735e3340ef90fc826b443975cf_112) |
| <u>[Item 5.](#i422a8f735e3340ef90fc826b443975cf_115)</u> | <u>[Other Information](#i422a8f735e3340ef90fc826b443975cf_115)</u> | [27](#i422a8f735e3340ef90fc826b443975cf_115) |
| <u>[Item 6.](#i422a8f735e3340ef90fc826b443975cf_121)</u> | <u>[Exhibits](#i422a8f735e3340ef90fc826b443975cf_121)</u> | [28](#i422a8f735e3340ef90fc826b443975cf_121) |

---

------

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this Quarterly Report are forward-looking statements, including without limitation, statements regarding:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the period over which we estimate our existing cash, cash equivalents and short-term investments will be sufficient to fund our future operating expenses and capital expenditure requirements, including that our existing cash, cash equivalent, and marketable securities will be sufficient to fund our obligations for at least 12 months after the issuance of the condensed consolidated financial statements included in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing, progress and results of preclinical studies and clinical studies for nimacimab, including any future studies or plans to evaluate combinations of nimacimab and incretin-based therapies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing, scope and likelihood of regulatory filings and approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expectations regarding the size, scope and design of future clinical studies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our manufacturing, commercialization, and marketing plans and strategies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our expectations regarding the approval and use of our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our competitive position and the development and impact of competing therapies that are or may become available;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the rate and degree of market acceptance and clinical utility of product candidates we may develop;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our future financial performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to raise capital to fund operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• statements relating to any pending litigation matters, including the Cunning Lawsuit; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the expected timing for reporting data from the Phase 2a extension study;

When used herein, words including "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "planning," "possible," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.

All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important risks and uncertainties, including, without limitation: the initiation and design of any future clinical trials of nimacimab will be impacted by the Company's capital resources, the Company's ability to obtain additional sources of capital needed to run an additional Phase 2 clinical trial, program considerations and potentially other factors outside the Company's control; the potential for additional weight loss after 26 weeks may not ultimately be observed; there is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and likewise it is possible that higher dosing will produce adversely different safety and tolerability results than those observed to date; the Company's dependence on third parties in connection with product manufacturing; research and preclinical and clinical testing; the Company's ability to advance, obtain regulatory approval of and ultimately commercialize nimacimab, competitive products or approaches limiting the commercial value of nimacimab; the timing and results of preclinical and clinical trials; the impact of any global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, adverse regulatory changes; the Company's ability to protect its intellectual property; risks associated with the Company's common stock; risks and uncertainties associated with the Cunning Litigation, and the other important factors discussed under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024, which are accessible on the SEC's website at www.sec.gov and the Investors section of the Company's website.

Any such forward-looking statements represent management's estimates as of the date of this Quarterly Report. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Quarterly Report.

------

**PART I - FINANCIAL INFORMATION**

**<u>Item 1. Financial Statements</u>**

------

**SKYE BIOSCIENCE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| | **(Unaudited)** | |
| **ASSETS** | | |
| **Current assets** | | |
| &nbsp;&nbsp;Cash and cash equivalents | $18441079 | $68415741 |
| &nbsp;&nbsp;Short-term investments | 16871229 |  |
| &nbsp;&nbsp;Prepaid expenses | 3712311 | 201962 |
| &nbsp;&nbsp;Other current assets | 900175 | 2209544 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 39924794 | 70827247 |
| Property and equipment, net | 1033965 | 1432752 |
| Operating lease right-of-use asset | 311620 | 449864 |
| Other assets | 53910 | 53910 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $41324289 | $72763773 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $2825005 | $569252 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll liabilities | 920774 | 1114255 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 2366123 | 654201 |
| &nbsp;&nbsp;&nbsp;&nbsp;Estimate for accrued legal contingencies and related expenses | 2054357 | 1818751 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability, current portion | 201638 | 182428 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 8367897 | 4338887 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability, net of current portion | 120207 | 273162 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 8488104 | 4612049 |
| **Commitments and contingencies (Note 7)** |  |  |
| **Stockholders' equity** |  |  |
| Preferred stock, $0.001 par value; 200,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 |  |  |
| Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 30,989,046 and 30,974,559 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 30989 | 30975 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in-capital | 205237719 | 199070421 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (172432523) | (130949672) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 32836185 | 68151724 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $41324289 | $72763773 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

------

**SKYE BIOSCIENCE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(UNAUDITED)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three Months Ended<br>September 30,** | **For the Three Months Ended<br>September 30,** | **For the Nine Months Ended<br>September 30,** | **For the Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;Research and development | $9357444 | $4883337 | $30892454 | $10908538 |
| &nbsp;&nbsp;General and administrative | 3907090 | 4638927 | 12375567 | 13171547 |
| &nbsp;&nbsp;Change in estimate for legal contingency |  | (4553468) |  | (4553468) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 13264534 | 4968796 | 43268021 | 19526617 |
| **Operating loss** | (13264534) | (4968796) | (43268021) | (19526617) |
| **Other (income) expense** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest (income) expense |  | (90766) |  | 796222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and other income, net | (418474) | (907697) | (1609807) | (2296488) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gains from asset sales | (91400) | (72837) | (180763) | (1217978) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expense |  | 801 |  | 2200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (income) expense, net | (509874) | (1070499) | (1790570) | (2716044) |
| **Loss before income taxes** | (12754660) | (3898297) | (41477451) | (16810573) |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes |  |  | 5400 | 10071 |
| **Net loss** | $(12754660) | $(3898297) | $(41482851) | $(16820644) |
| **Loss per common share:** |  |  |  |  |
| &nbsp;&nbsp;Basic | $(0.32) | $(0.10) | $(1.05) | $(0.48) |
| &nbsp;&nbsp;Diluted | $(0.32) | $(0.10) | $(1.05) | $(0.48) |
| **Weighted average shares of common stock outstanding used to compute loss per share:** |  |  |  |  |
| &nbsp;&nbsp;Basic | 39665927 | 38819387 | 39654512 | 35317352 |
| &nbsp;&nbsp;Diluted | 39665927 | 38819387 | 39654512 | 35317352 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

------

**SKYE BIOSCIENCE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
| | **For the Nine Months Ended<br>September 30,** | **For the Nine Months Ended<br>September 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net Loss | $(41482851) | $(16820644) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 543343 | 123347 |
| &nbsp;&nbsp;Stock-based compensation expense | 6149154 | 6228270 |
| &nbsp;&nbsp;Amortization of debt discount |  | 599006 |
| &nbsp;&nbsp;Gains from asset sales | (180763) | (1217978) |
| &nbsp;&nbsp;Write-down of vendor deposits |  | 325610 |
| &nbsp;&nbsp;Loss from disposal of assets |  | 10794 |
| &nbsp;&nbsp;Change in estimate for legal contingencies |  | (4553468) |
| &nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (3510349) | (470345) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 1309369 | (1606490) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets |  | (18000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 2187002 | (375760) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest - related party |  | (126027) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest - legal contingency |  | (234750) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll liabilities | (193481) | 14889 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability | (133745) | (52274) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 2016279 | 1109443 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (33296042) | (17064377) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;Proceeds from the sale of assets, net of sales costs | 180763 | 1217978 |
| &nbsp;&nbsp;Purchase of short-term investments, net of maturities | (16871229) |  |
| &nbsp;&nbsp;Purchase of property and equipment | (6312) | (1554003) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (16696778) | (336025) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;Purchase under employee stock purchase plan | 18158 |  |
| &nbsp;&nbsp;Proceeds from the issuance of common stock and warrants, net of equity issuance costs of $0 and $6,434,447, respectively  |  | 83556563 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 18158 | 83556563 |
| **Net (decrease) increase in cash, cash equivalents and restricted cash** | (49974662) | 66156161 |
| **Cash, cash equivalents and restricted cash, beginning of period** | $68415741 | $10336655 |
| **Cash, cash equivalents and restricted cash, end of period** | $18441079 | $76492816 |
| *Supplemental disclosures of cash-flow information:* |  |  |
| Reconciliation of cash, cash equivalents and restricted cash: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $18441079 | $67412614 |
| &nbsp;&nbsp;Restricted cash |  | 9080202 |
| Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows | $18441079 | $76492816 |
| *Supplemental disclosures of non-cash financing activities:* |  |  |
| &nbsp;&nbsp;Conversion of convertible note - related party to common stock | $— | $4971004 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

------

**SKYE BIOSCIENCE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(UNAUDITED)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **Total**<br>**Stockholders'**<br>**Equity** |
| | **Shares** | **Amounts** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **Total**<br>**Stockholders'**<br>**Equity** |
| **Balance, January 1, 2025** | **30974559** | $**30975** | $**199070421** | $**(130949672)** | $**68151724** |
| Stock-based compensation expense |  |  | 2201909 |  | 2201909 |
| Net loss for the three months ended March 31, 2025 |  |  |  | (11103319) | (11103319) |
| **Balance, March 31, 2025** | **30974559** | $**30975** | $**201272330** | $**(142052991)** | $**59250314** |
| Stock-based compensation expense | 3750 | 4 | 2033105 |  | 2033109 |
| Purchases under employee stock purchase plan | 9799 | 9 | 18149 |  | 18158 |
| Net loss for the three months ended June 30, 2025 |  |  |  | (17624872) | (17624872) |
| **Balance, June 30, 2025** | **30988108** | $**30988** | $**203323584** | $**(159677863)** | $**43676709** |
| Stock-based compensation expense | 938 | 1 | 1914135 |  | 1914136 |
| Net loss for the three months ended September 30, 2025 |  |  |  | (12754660) | (12754660) |
| **Balance, September 30, 2025** | **30989046** | $**30989** | $**205237719** | $**(172432523)** | $**32836185** |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **Total**<br>**Stockholders'**<br>**Equity/(Deficit)** |
| | **Shares** | **Amounts** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Deficit** | **Total**<br>**Stockholders'**<br>**Equity/(Deficit)** |
| **Balance, January 1, 2024** | **12349243** | $**12349** | $**102238382** | $**(104382549)** | $**(2131818)** |
| Stock-based compensation expense |  |  | 2478179 |  | 2478179 |
| Issuance of common stock and warrants, net of issuance costs of $6,434,447 | 15713664 | 15714 | 83540849 |  | 83556563 |
| Net loss for the three months ended March 31, 2024 |  |  |  | (5019531) | (5019531) |
| **Balance, March 31, 2024** | **28062907** | $**28063** | $**188257410** | $**(109402080)** | $**78883393** |
| Stock-based compensation expense | 5000 | 5 | 1828469 |  | 1828474 |
| Net loss for the three months ended June 30, 2024 |  |  |  | (7902816) | (7902816) |
| **Balance, June 30, 2024** | **28067907** | $**28068** | $**190085879** | $**(117304896)** | $**72809051** |
| Stock-based compensation expense |  |  | 1921617 |  | 1921617 |
| Conversion of convertible note - related party | 968973 | 969 | 4970035 |  | 4971004 |
| Exercise of pre-funded warrants | 1301410 | 1301 | (1301) |  |  |
| Net loss for the three months ended September 30, 2024 |  |  |  | (3898297) | (3898297) |
| **Balance, September 30, 2024** | **30338290** | $**30338** | $**196976230** | $**(121203193)** | $**75803375** |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

------

**SKYE BIOSCIENCE, INC. AND SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**1. Organization, Basis of Presentation and Significant Accounting Policies**

***Nature of Operations***

Skye Bioscience, Inc. (the "Company" or "Skye") was incorporated in Nevada on March 16, 2011. The Company is a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and related conditions.

As of September 30, 2025, the Company has devoted substantially all its efforts to securing its product pipeline, carrying out research and development, preparing for and conducting clinical trials, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.

*Impact of Geopolitical and Macroeconomic Factors*

It is possible that the Company may encounter supply chain issues related to global economic and political conditions such as a lack of production or laboratory resources, pandemics or cyberattacks that could cause business disruptions and clinical trial delays which will need to be managed in the future. There may also be significant uncertainty resulting from the impact of other geopolitical and macroeconomic factors, including global pandemics, tariffs, inflation, supply chain issues, fluctuating interest rates, future bank failures and increased geopolitical tensions between the U.S. and its international trade partners, including China. Further, the U.S. federal government has been shut down since October 1, 2025, and the impact of a prolonged government shutdown on business and economic conditions generally, and on our financial position specifically, is uncertain.

***Liquidity***

The Company has incurred operating losses and negative cash flows from operations since inception and as of September 30, 2025, had working capital of $31,556,897 and an accumulated deficit of $172,432,523. As of September 30, 2025, the Company had unrestricted cash and cash equivalents and short-term investments in the amount of $35,312,308. For the nine months ended September 30, 2025 and 2024, the Company incurred losses from operations of $43,268,021 and $19,526,617, respectively. For the nine months ended September 30, 2025 and 2024, the Company incurred net losses of $41,482,851 and $16,820,644, respectively. The Company expects to continue to incur significant losses through the end of 2025 and expects to incur significant losses and negative cash flows from operations in the future.

The Company's continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. During October 2025, the Company did not meet its primary endpoint in its Phase 2a study for nimacimab. As a result, management implemented a cost reduction plan to conserve runway while planning for potential future clinical studies and working to secure funding to support future clinical studies.

In January and March 2024, the Company completed two private placement equity transactions (the "January and March PIPE Financings") with institutional accredited investors in which we raised combined net aggregate proceeds of $83,556,563. The Company expects that the net proceeds raised from the January and March 2024 PIPE Financings will fund CBeyond studies for obesity through the 52-week Phase 2a extension data. However, additional funding will be required to support subsequent studies for the development of nimacimab.

In May 2024 the Company entered into an Equity Distribution Agreement (the "ATM Agreement") under which the Company may sell up to $100,000,000 of shares of common stock. The Company has not sold any shares under the ATM Agreement as of the date hereof and is not obligated to, and cannot provide any assurances that the Company will make any sales of the shares under the ATM Agreement.

The Company is a party to a legal proceeding with a former employee (see note 7). As of September 30, 2025, the estimated legal contingency, including accrued legal expenses, is $2,054,357.

It is possible that the Company may encounter issues relating to supply chain inefficiencies, a lack of production or laboratory resources, global economic and political conditions, pandemics or cyberattacks that could cause business disruptions and clinical trial delays which will need to be managed in the future.

------

The Company does not believe that inflation has had a material impact on its operating results during the periods presented. However, inflation has had, and may continue to have, an impact on general and administrative costs such as professional fees, employee costs and travel costs, and may in the future adversely affect the Company's operating results. In addition, increased inflation has had and may continue to have an effect on interest rates. Increased interest rates may adversely affect the terms under which the Company can obtain any potential additional funding.

Notably, the Company relies on third party manufacturers to produce its product candidates. The manufacturing of nimacimab is conducted in Europe. Formulation for clinical trial use relies on regulatory-accepted excipients that can be sourced from countries outside the United States.

***Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year, or any future periods.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates

The unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, from which the prior year balance sheet information herein was derived.

Certain reclassifications have been made to the amounts in prior periods to conform to the current period's presentation, including reclassifying discovery research and development expense amounts from external clinical development expenses into other research and development expenses, as described in Note 8, Segment Reporting. Such reclassifications did not have a material impact on the accompanying unaudited condensed consolidated financial statements.

During the nine months ended September 30, 2025, there were no changes to the Company's significant accounting policies as described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

***Pronouncements Implemented***

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity's exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company adopted this ASU as of January 1, 2025. The company is evaluating the impact this ASU will have on its upcoming annual filing on the Form 10-K for the year ended December 31, 2025.

***Recent Accounting Pronouncements Not Yet Adopted***

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional disclosure of the nature of expenses included in the income statement. The standard requires disclosures about specific types of expenses included in the expense captions presented in the income statement as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.

------

**2. Fair Value Measurement**

The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

---

| | | |
|:---|:---|:---|
| | **Fair Value Measurement as of September 30, 2025** | **Fair Value Measurement as of September 30, 2025** |
| | **Valuation** | |
| | **Hierarchy** | **Total** |
| Assets: |  |  |
| Money market funds (included in cash and cash equivalents) | Level 1 | $12278725 |
| U.S. treasury obligations (included in short-term investments) | Level 1 | 16871229 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents and marketable securities |  | $**29149954** |

---

**3**. **Prepaid Expenses, Other Current Assets and Liabilities**

Prepaid expenses consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Prepaid clinical expenses | $3353640 | $13078 |
| Prepaid insurance | 126713 | 60007 |
| Other prepaid expenses | 231958 | 128877 |
|  | $**3712311** | $**201962** |

---

Other current assets consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Vendor deposits | 706399 | 1997274 |
| Other tax receivables | 16757 | 13216 |
| Other current assets | 177019 | 199054 |
|  | $**900175** | $**2209544** |

---

Other current liabilities consist of the following:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Research and development costs | $2122260 | $325415 |
| Legal expenses | 91103 | 114359 |
| Consulting and professional fees | 89168 | 109375 |
| Other accrued liabilities | 63592 | 105052 |
|  | $**2366123** | $**654201** |

---

------

**4. Warrants** 

There are significant judgements and estimates inherent in the determination of the fair value of the Company's warrants. These judgements and estimates include assumptions regarding the Company's future operating performance and the determination of the appropriate valuation methods.

Warrants vested and outstanding as of September 30, 2025, are summarized as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Source** | **Exercise<br>Price** | **Weighted<br>Average<br>Remaining<br>Contractual<br>Term<br>(Years)** | **Number of<br>Warrants<br>Outstanding** |
| 2016 Common Stock Warrants to Service Providers | 287.50 | 1.08 | 160 |
| 2021 Inducement Warrants | 37.50 | 0.82 | 84667 |
| 2021 Inducement Warrants to Placement Agent | 47.00 | 0.82 | 5927 |
| 2021 Common Stock Warrants | 22.50 | 0.99 | 311113 |
| 2021 Common Stock Warrants to Placement Agent | 27.50 | 0.99 | 21778 |
| August 2023 Convertible Note Common Stock Warrants | 5.16 | 7.88 | 340000 |
| August 2023 PIPE Financing Common Stock Warrants | 5.16 | 7.88 | 2325537 |
| January 2024 Pre-Funded Warrants Common Stock | 0.001 | Indefinite | 8677166 |
| **Total warrants outstanding as of September 30, 2025** |  |  | **11766348** |

---

As of September 30, 2025, all of the Company's warrants are fully vested*.*

**5. Stock-Based Compensation**

***Stock Incentive Plan***

On October 31, 2014, the Board of Directors of the Company (the "Board") approved the Company's 2014 Omnibus Incentive Plan (the "2014 Omnibus Incentive Plan"). On June 14, 2022, the Board approved the 2014 Amended and Restated Omnibus Incentive Plan (the "2014 Amended and Restated Plan") which replaced the 2014 Omnibus Incentive Plan in its entirety.

On September 29, 2023, the Board and holders of a majority of the voting power of the outstanding capital stock of the Company adopted and approved Amendment No. 1 to the 2014 Amended and Restated Plan. Amendment No. 1 to the 2014 Amended and Restated Plan became effective on November 6, 2023.

On October 22, 2024, the second amendment and restatement of the Company's 2014 Amended and Restated Plan was approved to increase the number of shares of the Company's common stock issuable to 4,000,000, extend the expiration date of the plan to September 10, 2034, update the name of the plan to the "Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan" and make certain administrative amendments (as so amended and restated, the "Amended and Restated Plan").

As of September 30, 2025, the Company had 165,785 shares available for future grant under the Amended and Restated Plan.

***2024 Inducement Equity Incentive Plan***

On July 2, 2024, the Board adopted the Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). The Company has reserved 600,000 shares of the Company's common stock for issuance pursuant to awards granted under the Inducement Plan. As of September 30, 2025, the Company had 142,500 shares available for future grant under the Inducement Plan.

------

***Stock Options***

The following is a summary of option activity under the Company's Amended and Restated Plan and the Inducement Plan, for the nine months ended September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of<br>Shares** | **Weighted<br>Average<br>Exercise Price** | **Weighted<br>Average<br>Remaining<br>Contractual<br>Term (Years)** | **Aggregate Intrinsic Value\*** |
| **Outstanding, December 31, 2024** | **3036603** | $**7.72** | **8.91** | $**22624** |
| Granted | 1697200 | 3.01 |  |  |
| Cancelled | (7211) | 18.49 |  |  |
| Forfeited | (44000) | 4.27 |  |  |
| **Outstanding, September 30, 2025** | **4682592** | $**6.03** | **8.65** | $**1742437** |
| **Exercisable, September 30, 2025** | **1742216** | $**7.70** | **7.77** | $**384264** |

---

*\*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2025 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options").*

The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2025, was $2.20.

The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** |
| Dividend yield | 0.00% | 0.00% |
| Volatility | 83.86 - 85.93% | 81.73 - 99.96% |
| Risk-free interest rate | 3.87- 4.27% | 3.69 - 4.48% |
| Expected term (years) | 5.27- 6.08 | 5.27 - 6.08 |

---

***Restricted Stock Units***

The following is a summary of restricted stock unit ("RSU") activity during the nine months ended September 30, 2025:

---

| | | |
|:---|:---|:---|
| | **Number of<br>Shares** | **Weighted**<br>**Average Grant Date Fair Value** |
| **Unvested, December 31, 2024** | **503113** | $**9.62** |
| Vested | (4687) | 7.56 |
| **Unvested, September 30, 2025** | **498426** | $**9.63** |

---

------

***2022 Employee Stock Purchase Plan***

In June 2022, the Board approved the 2022 Employee Stock Purchase Plan (the "ESPP"), under which the Company may offer eligible employees the option to purchase common stock at a 15% discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of the ESPP. Total individual purchases in any year are limited to 15% of compensation. The ESPP was approved by the Company's stockholders on September 30, 2022. As of September 30, 2025, 9,799 shares were issued under the ESPP.

***Stock-Based Compensation Expense***

The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period or derived service period. The Company recognized stock-based compensation expense for the stock options, ESPP, and the RSUs discussed above, in its unaudited condensed consolidated statements of operations as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Research and development | $550491 | $360845 | $1559097 | $1056564 |
| General and administrative | 1363645 | 1560772 | 4590057 | 5171706 |
|  | $**1914136** | $**1921617** | $**6149154** | $**6228270** |

---

The total amount of unrecognized compensation cost was $12,200,136 as of September 30, 2025. This amount will be recognized over a weighted average period of 2.64 years.

**6. Loss Per Share of Common Stock**

The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Basic EPS and diluted EPS:** |  |  |  |  |
| **Loss (Numerator)** |  |  |  |  |
| Net loss | $(12754660) | $(3898297) | $(41482851) | $(16820644) |
| **Shares (Denominator)** |  |  |  |  |
| Weighted average common shares outstanding \*\* | 39665927 | 38819387 | 39654512 | 35317352 |
| **Per-Share Amount** | $**(0.32)** | $**(0.10)** | $**(1.05)** | $**(0.48)** |

---

*\*\* The denominator considers the outstanding pre-funded warrants as common stock equivalents in calculating weighted average common shares outstanding.*

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Stock options | 4682592 | 1639354 | 4682592 | 1639354 |
| Warrants | 3089182 | 3272940 | 3089182 | 3272940 |
| Unvested restricted stock units | 498426 | 513446 | 498426 | 513446 |

---

------

**7. Contingencies** 

***General Litigation and Disputes***

From time to time, in the normal course of operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Company's operations or financial position, liquidity or results of operations.

*Wendy Cunning vs Skye Bioscience, Inc.*

The Company is a party to a legal proceeding with a former employee alleging, among other things, wrongful termination, violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law against the Company relating to certain actions and events that occurred with the Company's former management during the employee's employment term from March 2018 to July 2019. The complaint seeks unspecified economic and non-economic losses, as well as attorneys' fees. The case, entitled *Wendy Cunning vs Skye Bioscience, Inc.*, was filed in U.S. District Court (the "District Court") for the Central District of California (the "Cunning Lawsuit"). On January 18, 2023, a jury rendered a verdict in favor of the plaintiff and awarded her $512,500 in economic damages (e.g., lost earnings, future earnings and interest), $840,960 in non-economic damages (e.g., emotional distress) and $3,500,000 in punitive damages. On August 2, 2023, the District Court ruled on the plaintiff's motion for attorney fees and awarded the plaintiff $1,200,008. Based on this order, the Company reduced the aggregate estimate for the legal contingency by $151,842, the difference between the attorney fees awarded by the District Court and the Company's previous estimate. On August 17, 2023, the Company obtained a stay on enforcement of the judgment in the Cunning Lawsuit by posting an appeal bond in the amount of $9,080,202.

In March of 2023, the Company appealed the judgment in the Cunning Lawsuit to the United States Court of Appeals for the Ninth District (the "Ninth Circuit"). On October 22, 2024, the Ninth Circuit issued its decision in the Company's favor which vacated the judgment and remanded the case back to the District Court for a new trial. As a result, the Company recovered the $9,080,202 restriction on its cash related to the bond during the year ended December 31, 2024. The new trial is currently scheduled to be held in February 2026.

During the year ended December 31, 2024, management revised its assumptions related to its estimate of the legal contingency and the Company reversed the accrued interest on the original judgment and recognized a gain of $4,234,717 in change in estimate for legal contingencies. As of September 30, 2025, the estimated legal contingency, including accrued legal expenses, is $2,054,357.

In arriving at the conclusion that a significant portion of the estimated legal contingency should be reversed, the Company considered the following in revising its assumptions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advice from external advisors including its technical accounting advisors regarding the appropriate application of GAAP and legal counsel's advice with regard to prior experience with similar cases,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the damages and potential attorney fee awards if the case were to be retried, including the likelihood of a subsequent loss if the Company were to be unsuccessful, while giving consideration to the facts and circumstances that would be inadmissible due to the Ninth Circuit's decision,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the likelihood of settlement and information obtained during settlement discussions prior to the first trial,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Company's possible defenses and counterclaims, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the case history and the amount of the prior judgment.

The final amount of the loss and loss recoveries remain uncertain. The ultimate amount of the potential loss may be significantly less than the amount of the revised legal contingency and there is no guarantee that the Company will be successful in its efforts to recover additional losses. The Company believes that it is at least reasonably possible that the estimated amount of the potential loss may change in the near term.

------

**8. Segment Reporting**

The Company operates in one business segment, which includes the business of research and development activities related to developing medicine for obesity and other metabolic diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company's chief operating decision maker ("CODM"). The Company's CODM is its Chief Executive Officer, who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

In addition to the significant expense categories included within consolidated net loss presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses which are presented to the Company's CODM for review:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| External clinical development expenses <sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SBI-100 | $8270 | $110580 | $10511 | $2118397 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;nimacimab | 6889483 | 3406919 | 23528123 | 5212012 |
| Total External clinical development expenses | 6897753 | 3517499 | 23538634 | 7330409 |
| Personnel related and stock-based compensation | 1495889 | 1108889 | 4241662 | 2765541 |
| Other research and development expenses <sup>(2)</sup> | 963802 | 256949 | 3112158 | 812588 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total research and development expenses | $**9357444** | $**4883337** | $**30892454** | $**10908538** |

---

(1) External clinical development expenses include expenses for clinical trial costs and clinical manufacturing.

(2) Other research and development expenses include expenses for travel and entertainment, consulting and advisory, discovery research and development, and general business expenses.

The net book value of property and equipment in the US was equal to $64,014 and $83,276 for September 30, 2025, and December 31, 2024, respectively. The net book value of property and equipment outside of the US was equal to $969,950, and $1,349,476 for September 30, 2025, and December 31, 2024, respectively.

**9. Subsequent Events**

***Prefunded Warrant Exercise***

Subsequent to September 30, 2025, 1,060,000 pre-funded warrants with an intrinsic value of $2,014,000 were cashless exercised in exchange for 1,059,441 shares of common stock.

------

**<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.</u>**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements (unaudited) for the three and nine months ended September 30, 2025 and 2024, together with the notes thereto and the consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (SEC) on March 20, 2025.* 

*Solely for convenience, certain trademark and service marks (the "marks") referred to in this Quarterly Report on Form 10-Q*

*appear without the® or™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to*

*the fullest extent under applicable law, our rights to these marks.*

*Unless otherwise provided in this Quarterly Report on Form 10-Q, references to "we," "us," "our" and "Skye" in this discussion and analysis refer to Skye Bioscience, Inc., a Nevada corporation, together with its consolidated subsidiaries.*

**Overview**

We are a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and related conditions. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting the CB1 receptor.

We are conducting CBeyond<sup>TM</sup>, a Phase 2a proof-of-concept clinical trial of nimacimab administered as a subcutaneous injectable for the treatment of obesity and overweight in the United States. The randomized, placebo- and active-controlled, double-blind CBeyond Phase 2a trial enrolled 136 adults with obesity or overweight, including individuals with a BMI ≥27 kg/m² with at least one comorbidity. Patients were randomized across four arms, 2:2:1:1 to arms with weekly nimacimab 200 mg subcutaneously, placebo, nimacimab 200 mg plus semaglutide (Wegovy®), or placebo plus semaglutide, and were dosed weekly for 26 weeks. Patients not participating in a 26-week extension were monitored for 13 weeks post-treatment.

In October 2025, we reported the following 26 week topline data from our ongoing CBeyond study:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In CBeyond, the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo, mITT). Preliminary pharmacokinetic analysis showed an association between exposure and response, suggesting that the 200 mg, subcutaneous weekly dose was suboptimal as a monotherapy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• At the tested dose and exposure levels, nimacimab 200 mg demonstrated a favorable safety profile with placebo-like tolerability. In combination with semaglutide, there was no increase in gastrointestinal (GI) adverse events. Importantly, there were no increases in neuropsychiatric adverse events reported resulting from treatment with nimacimab.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the combination arm, nimacimab 200 mg, subcutaneous weekly dose plus semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to semaglutide alone (-13.2% vs -10.25%, p=0.0372, mITT), with no plateau being observed through Week 26. In the combination arm, 100% of patients achieved greater than 5% weight loss (vs. 85% with semaglutide alone) and 67% achieved greater than 10% weight loss (vs. 50% with semaglutide alone) based on the per protocol analysis. This finding supports potential further studies to evaluate combinations of nimacimab and incretin-based therapies. Other findings in the combination arm included:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Nimacimab plus semaglutide showed a change of -11.26cm (1.16cm) in waist circumference versus -8.09cm (1.2cm) for semaglutide alone, resulting in a difference of -3.17cm (1.59cm) (p=0.0492, using least-squares mean (LSM)).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ An improvement in lean mass to fat mass ratio was observed at week 26 when comparing the nimacimab plus semaglutide combination arm to the placebo arm (0.26 vs. 0.02, p <0.0001), and the combination arm compared to semaglutide alone (0.26 vs. 0.13, p = 0.0126).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ A decrease in rebound weight gain in an analysis of participants 12 weeks post-treatment when nimacimab 200 mg (subcutaneous, weekly) was combined with semaglutide when compared to semaglutide alone (18.1% versus 49.8% weight rebound). Moreover, at 12 weeks post-treatment, the nimacimab plus semaglutide group maintained significant weight loss compared to the placebo group (p=0.006), while the semaglutide alone group lost significance over the placebo group (p=0.12) and followed a trajectory of rebound weight gain consistent with previously reported data (Wilding et al., 2022, STEP-1 Trial Extension), which demonstrated that patients will gain a majority of weight back within 1-year of stopping treatment with semaglutide.

------

Patients who completed 26 weeks of treatment in the primary phase of the study were eligible to enroll in a 26-week extension for a potential full treatment duration of 52 weeks with a 13-week follow-up period. In September 2025, we completed the enrollment in the extension study. A total of 43 patients were enrolled, with 19 and 24 patients in the combination and monotherapy cohorts, respectively. In the combination arms, patients will continue with blinded treatment with nimacimab or placebo and will continue receiving semaglutide (Wegovy®). Patients in the monotherapy arm will receive nimacimab 300 mg during the extension. Enrollment for the extension is complete. Skye expects to report data from the extension study in Q1 2026.

We believe multiple factors support evaluation of nimacimab at higher doses, including the combination of preclinical toxicology safety margins and modeling; preclinical pharmacology data showing dose-dependent increases in weight loss with nimacimab monotherapy and GLP-1 combinations; and the notable safety profile in the Phase 2a study. However, there can be no assurance that nimacimab at higher doses will result in the desired end points.

We were incorporated under the laws of the State of Nevada on March 16, 2011. Our headquarters are based in San Diego, CA, and we also maintain administrative office space in San Francisco, CA. Since our incorporation, we have devoted substantially all of our efforts to building our product portfolio through the acquisition of clinical assets and licensing agreements, carrying out research and development, building infrastructure and raising capital.

**Financial Overview**

*Revenues*

To date, we have not generated any revenue. We do not expect to receive any revenue from our drug candidate, nimacimab, or any future drug candidates that we develop unless and until we obtain regulatory approval for, and commercialize, nimacimab or future drug candidates or generate revenue from collaborative agreements with third parties.

*Research and Development Expenses*

During the three and nine months ended September 30, 2025, we incurred $9,357,444 and $30,892,454 in research and development expenses primarily related to our Phase 2a clinical trial of nimacimab for obesity and the manufacturing costs associated with future trials. During the three and nine months ended September 30, 2024, we incurred $4,883,337 and $10,908,538 in research and development expense primarily related to our efforts in conducting our Phase 2a clinical trial for SBI-100 OE and costs related to our Phase 2a clinical trial for nimacimab for obesity.

We expect that our ongoing research and development expenses will consist of costs incurred for the development of our drug candidate, nimacimab, or any future drug candidates, including but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• employee-related expenses, which include salaries, benefits and stock-based compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• payments to third party contract research organizations and investigative sites;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• payments to third party manufacturing organizations and consultants; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• payments to third parties related to our discovery research and development efforts to build our pipeline.

We expect to incur future research and development expenditures to support our preclinical, nonclinical, and clinical studies. Preclinical and nonclinical activities include early discovery efforts with novel molecules, laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess safety and efficacy.

The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming and the successful development of our drug candidate, nimacimab, and any future drug candidate is highly uncertain. Our future research and development expenses will depend on the clinical success of nimacimab and any future drug candidates as well as ongoing assessments of the commercial potential of such drug candidates. In addition, we cannot forecast with any degree of certainty whether nimacimab or any future drug candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect to incur increased research and development expenses in the future as we continue our efforts towards advancing our lead program for nimacimab.

*General and Administrative Expenses*

Our general and administrative expenses have fluctuated year-over-year as we have entered into various strategic acquisitions to restructure and reposition our company. Additionally, as a business in the early stages of drug development we are in the process of scaling our operations by hiring additional employees and building the infrastructure necessary to increase efficiencies. These initiatives have resulted in additional costs related to the implementation of certain systems, insurance, facilities, legal, tax and accounting costs. As a public company, we expect to incur additional expenses related to insurance,

------

investor relations activities, legal and other administration and professional services to comply with the rules and regulations of the SEC, the Financial Industry Regulatory Authority ("FINRA") and Nasdaq. Other significant costs are expected to include legal fees relating to patent and corporate matters, business development costs and fees for consulting services. To incentivize our employees and be competitive to retain strong talent we issued additional equity awards in 2025 and 2024, which have resulted in increased stock-based compensation expense. We also expect that certain general and administrative expenses which are commensurate with headcount, will continue to increase in the future in order to support our expected increase in research and development activities, including increased salaries, technology, facilities and other related costs.

*Estimate for Legal Contingencies and Related Expenses*

The estimate for legal contingencies and related expenses relates to a litigation matter that related to a former employee of the Company. As of December 31, 2023, we had posted an appellate bond that was collateralized by an irrevocable letter of credit equal to, $9,080,202, approximately 150% of the liability recorded on our balance sheet. As of December 31, 2024, we were successful in our appeal of the judgment in the Ninth Circuit Court of Appeals and the case was remanded back to the District Court for a new trial, as a result of which we reduced the estimated legal contingency based on new key assumptions. The final amount of the loss and loss recoveries remains uncertain. We believe that it is at least reasonably possible that the estimated amount of the potential loss may change in the near term. As of September 30, 2025, the estimated legal contingency, including accrued legal expenses, is $2,054,357.

*Other (Income) Expense*

Other (income) expense primarily includes a gain from the sale of the Avalite Sciences, Inc. ("AVI") building (the "AVI building") in the first quarter of 2024, and interest expense. These expenses are offset by interest income earned on our cash and cash equivalent balances and short term investments.

**Critical Accounting Estimates**

There have been no material changes in our Critical Accounting Estimates from the information provided in the "Critical Accounting Estimates" section of "Item 7- Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

**Recently Issued and Adopted Accounting Pronouncements**

See Note 1 to the accompanying unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for information on recently issued accounting pronouncements and recently adopted accounting pronouncements. While we expect certain recently adopted accounting pronouncements to impact our disclosures in future periods, the impact upon adoption was not significant to our current estimates and operations.

**Results of Operations**

***For the three months ended September 30, 2025 and 2024***

*Research and Development Expenses*

Below is a summary of our research and development expenses during the three months ended September 30, 2025 and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | **2024** | **$ Change<br>2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| Research and development expenses | $9357444 | $4883337 | $4474107 | 92% |

---

Research and development expenses for the three months ended September 30, 2025, increased by $4,474,107 as compared to the same period in 2024. The net increase in research and development expenses was primarily due to:

• Clinical trial costs increased by $578,014 due to increased site and patient costs related to our Phase 2a clinical study for nimacimab.

• Contract manufacturing costs increased by $2,704,671 from drug substance, product, labeling and packaging costs related to resupplying our extended Phase 2a clinical study for nimacimab, manufacturing in anticipation for our clinical study of nimacimab, and process intensification and dose optimization work.

------

• Discovery research and development costs increased $479,430 from increased work to interrogate nimacimab's mechanism of action and for life cycle management.

• Quality assurance costs increased by $100,653 from routine vendor site audits.

• Salaries and stock-based compensation increased by $387,000 due to increased headcount.

• General business expenses decreased by $139,664 due to the non-recurrence of fees associated with eliminating our glaucoma program.

• Consulting, advisory and professional fees increased by $353,956 to support our nimacimab program.

• Depreciation expense on equipment increased by $59,243 due to the depreciation of manufacturing equipment.

*General and Administrative Expenses*

Below is a summary of our general and administrative expenses during the three months ended September 30, 2025, and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | **2024** | **$ Change<br>2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| General and administrative expenses | $3907090 | $4638927 | $(731837) | (16)% |

---

General and administrative expenses for the three months ended September 30, 2025, decreased by $731,837 as compared to the same period in 2024. The decrease in general and administrative expenses was primarily due to:

• Salaries, benefits and other direct employee related costs decreased by $209,163 primarily due to lower headcount and timing of new hires.

• Consulting, advisory and professional fees decreased by $496,410 primarily due to the timing of tax accounting services and financial advisory services.

• Investor relations, marketing and communications expenses increased by $50,022 primarily due to additional content creation and digital marketing expenses.

• Recruiting fees decreased by $272,699 primarily due to the one time cost to hire an executive in the prior period.

• Legal and professional fees increased by $171,707 due to increased patent prosecution activity and litigation defense costs.

*Change in Estimate for Legal Contingencies*

Total change in estimate for legal contingencies for the three months ended September 30, 2025 and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | **2024** | **$ Change<br>2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| Change in estimate for legal contingencies | $— | $(4553468) | $4553468 | (100)% |

---

For the three months ended September 30, 2024, we recorded a change in estimate for legal contingencies (as defined in Note 7 to the accompanying Unaudited Condensed Consolidated Financial Statements) based on changes after September 30, 2024 to the facts and circumstances related to our legal proceedings that existed as of the balance sheet date.

------

*Other (Income) Expense* 

Below is a summary of our other (income) expense for the three months ended September 30, 2025 and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
| | **2025** | **2024** | **$ Change<br>2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| Interest (income) expense | $— | $(90766) | $90766 | (100)% |
| Interest and other income, net | (418474) | (907697) | 489223 | (54)% |
| Gains from asset sales | (91400) | (72837) | (18563) | 25% |
| Other expense |  | 801 | (801) | (100)% |
| **Total other income** | $**(509874)** | $**(1070499)** | $**560625** | **(52)%** |

---

For the three months ended September 30, 2025, we had an decrease of other income of $560,625 as compared to the same period in 2024 primarily due to:

• Increased interest income of $90,766 due to the reversal of accrued interest on the legal judgment, which was vacated in the prior year.

• Decreases in interest income and other income of $489,223 due to decreased interest from our cash equivalents and short-term investments yields as a result of the decrease in cash equivalents and short-term investments on hand.

***For the nine months ended September 30, 2025 and 2024***

*Research and Development Expenses*

Below is a summary of our research and development expenses during the nine months ended September 30, 2025, and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **$ Change<br>2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| Research and development expenses | $30892454 | $10908538 | $19983916 | 183% |

---

Research and development expenses for the nine months ended September 30, 2025, increased by $19,983,916 as compared to the same period in 2024. The net increase in research and development expenses was primarily due to:

• Clinical trial costs increased by $4,203,355 due to increased site and patient costs related to our the extension of the Phase 2a clinical study of nimacimab, offset by a decrease in costs to complete our glaucoma study.

• Contract manufacturing costs increased by $11,854,544 from drug substance, product, labeling and packaging costs related to resupplying the extension of our Phase 2a clinical study of nimacimab, manufacturing drug substance for the next CBeyond clinical study for nimacimab, and process intensification and dose optimization work.

• Discovery research and development increased $1,824,126 from increased work to interrogate nimacimab's mechanism of action, potency and for life cycle management.

• Salaries, benefits and stock-based compensation increased by $1,476,121 due to increased headcount.

• Consulting, advisory and professional fees increased by $603,719 to support our nimacimab program.

• General business expenses decreased by $402,409 due to the non-recurrence of fees associated with eliminating our glaucoma program.

• Depreciation expense on equipment increased by $249,087 due to the depreciation of manufacturing equipment.

------

*General and Administrative Expenses*

Below is a summary of our general and administrative expenses during the nine months ended September 30, 2025, and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **$ Change**<br>**2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| General and administrative expenses | $12375567 | $13171547 | $(795980) | (6)% |

---

General and administrative expenses for the nine months ended September 30, 2025, decreased by $795,980 as compared to the same period in 2024. The decrease in general and administrative expenses was primarily due to:

• Salaries, benefits and other direct employee related costs decreased by $56,293 primarily due to lower headcount and timing of new hires.

• Professional, consulting and advisory fees decreased by $518,287 primarily due to the decrease in professional fees from tax and financial advisory services.

• Recruiting fees expenses decreased by $219,935 due to the one time cost to hire an executive in the prior period.

• Investor relations, marketing and communications expenses increased by $615,111 due primarily to a market evaluation study for nimacimab and increased investor communications activities.

• Legal and professional fees decreased by $291,197 due to decreases in litigation, one-time fees related to SEC filings in the prior period, decreases in external legal costs and decreased financial advisory services.

*Change in Estimate for Legal Contingencies*

Total change in estimate for legal contingencies for the nine months ended September 30, 2025 and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **$ Change**<br>**2025 vs. 2024** | **% Change**<br>**2025 vs. 2024** |
| Change in estimate for legal contingencies | $— | $(4553468) | $4553468 | (100)% |

---

For the nine months ended September 30, 2024, we recorded a change in estimate for legal contingencies (as defined in Note 7 to the accompanying Unaudited Condensed Consolidated Financial Statements) based on changes after September 30, 2024 to the facts and circumstances related to our legal proceedings that existed as of the balance sheet date.

*Other (Income) Expense* 

Below is a summary of our other (income) expense for the nine months ended September 30, 2025 and for the same period in 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **$ Change**<br>**2025 vs. 2024** | **% Change<br>2025 vs. 2024** |
| Interest (income) expense | $— | $796222 | (796222) | (100)% |
| Interest and other income, net | (1609807) | (2296488) | 686681 | (30)% |
| Gains from asset sales | (180763) | (1217978) | 1037215 | (85)% |
| Other expense |  | 2200 | (2200) | (100)% |
| **Total other income** | $**(1790570)** | $**(2716044)** | $**925474** | **(34)%** |

---

For the nine months ended September 30, 2025, we had a reduction of other (income) expense of $925,474 as compared to the same period in 2024 primarily due to:

• Gain on sale of asset decreased by $1,037,215, due to the one-time sale of real estate during the nine months ended September 30, 2024.

• Decreased interest expense of $796,222 due to the reduction of debt.

------

• Decreased interest income and other income of $686,681 due to the decreased interest from our cash and cash equivalents and short-term investments yields as a result of the decrease in cash equivalents and short-term investments on hand.

**Liquidity and Capital Resources** 

***Liquidity***

We have incurred operating losses and negative cash flows from operations since our inception, and as of September 30, 2025, we had working capital of $31,556,897, an accumulated deficit of $172,432,523, and stockholders' equity of $32,836,185. We had unrestricted cash and cash equivalents and short-term investments in the amount of $35,312,308 as of September 30, 2025, as compared to $68,415,741 as of December 31, 2024. For the nine months ended September 30, 2025 and 2024, the Company incurred losses from operations of $43,268,021 and $19,526,617, respectively. For the nine months ended September 30, 2025 and 2024, the Company incurred net losses of $41,482,851 and $16,820,644, respectively.

In January and March 2024, we completed two private placement equity transactions (the "January and March PIPE Financings") with institutional accredited investors in which we raised combined net aggregate proceeds of $83,556,563. We expect that the net proceeds raised from the January March 2024 PIPE Financings, will continue to allow us to fund CBeyond studies for obesity through the 52 week Phase 2a extension data, progress formulation development activities related to dose concentration and process intensification, manufacture drug substance for the next study of nimacimab for obesity and provide us with the ability to expand upon our metabolic program with our other research and development efforts. Accordingly, we will require additional funds in order to initiate the next CBeyond study, including through public or private equity or debt financings, other sources, or through strategic collaborations.

In May 2024 we entered into an Equity Distribution Agreement (the "ATM Agreement") with Piper Sandler & Co., as the sales agent (the "Sales Agent") under which the Company may sell up to $100,000,000 of shares of common stock through the Sales Agent. The Company has not sold any shares under the ATM Agreement as of the date hereof and is not obligated to, and cannot provide any assurances that the Company will make any sales of the shares under the ATM Agreement.

In August 2024, the holder of a secured promissory note exercised their conversion option and converted the principal balance of $5,000,000 into 968,973 shares of our common stock.

During the fourth quarter of 2024, we were successful in our appeal in the Ninth Circuit of the judgment of a material litigation matter, which has been remanded to the District Court for a new trial, and the bond related to the judgment was exonerated, allowing us to recover $9,000,000 in restricted cash. Additionally, in a related case with our insurance carrier, we collected $2,000,000 during the fourth quarter of 2024. The recovered funds have been reallocated to further our clinical pipeline and extend our cash runway.

The Company's unaudited condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Based on its current operational requirements, the Company believes that its current cash will be sufficient to fund its projected operations for at least 12 months from the date of the issuance of these consolidated financial statements. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. Accordingly, we may need to seek additional funds sooner than planned, including through public or private equity or debt financings, other sources, or through strategic collaborations. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.

Our future capital requirements will depend on many factors, including:

• the scope, rate of progress, results and costs of our clinical trials, preclinical studies and other related activities;

• our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

• the timing of, and the costs involved in, obtaining regulatory approvals for nimacimab or any future drug candidates;

• the number and characteristics of the drug candidates we seek to develop or commercialize;

• the cost of manufacturing clinical supplies, and establishing commercial supplies of our drug candidates, both in the U.S. and internationally;

• the cost of commercialization activities if our current or future drug candidates are approved for sale, including marketing, sales and distribution costs;

------

• the expenses needed to attract and retain skilled personnel;

• the costs associated with being a public company;

• the amount of revenue, if any, received from commercial sales of our drug candidates, should any of our drug candidates receive marketing approval;

• the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation;

• the results of the new trial in the litigation matter discussed above under "--General Litigation and Disputes — Wendy Cunning vs. Skye Bioscience, Inc." and "--Financial Overview — Estimated Legal Contingency"; and

• the impact of any of the foregoing of macroeconomic events, including inflation, fluctuating interest and exchange rates, and market volatility as a result of trade, fiscal and regulatory policies, including tariffs and any effects of a prolonged government shutdown.

*Cash Flows*

The following is a summary of our cash flows for the periods indicated and has been derived from our unaudited condensed consolidated financial statements which are included elsewhere in this Quarterly Report on Form 10-Q:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** |
| Net cash used in operating activities | $(33296042) | $(17064377) |
| Net cash used in investing activities | (16696778) | (336025) |
| Net cash provided by financing activities | 18158 | 83556563 |

---

*Cash Flows from Operating Activities* 

The primary use of cash for our operating activities during the period was to fund research development activities for our clinical product candidate and general and administrative activities. Our cash used in operating activities also reflected changes in our working capital, net of adjustments for non-cash charges, such as stock-based compensation, depreciation and amortization, amortization of debt discount and the gain on sale of asset.

Cash used in operating activities of $33,296,042 during the nine months ended September 30, 2025, reflected a net loss of $41,482,851, partially offset by aggregate non-cash charges of $6,511,734 and included a $1,675,075 net cash inflow in our operating assets and liabilities.

Non-cash charges included $6,149,154 for stock-based compensation expense primarily attributable to the recognition of current period expense on prior grants and $543,343 in depreciation and amortization. The net change in our operating assets and liabilities included a $2,200,980 cash outflow from the increase in our prepaid expenses and other current assets, a $1,689,053 net cash inflow from increase in our accrued expenses and other current liabilities and a $2,187,002 cash inflow from the increase of our accounts payable.

Cash used in operating activities of $17,064,377 during the nine months ended September 30, 2024, reflected a net loss of $16,820,644, partially offset by aggregate non-cash charges of $1,515,581 and included a $1,759,314 net change in our operating assets and liabilities.

*Cash Flows from Investing Activities* 

During the nine months ended September 30, 2025, our cash used in investing activities related primarily to the purchase, net of maturities, of $16,871,229 in short-term investments and $180,763 in net proceeds from the sale of the AVI building.

During the nine months ended September 30, 2024, the Company purchased $1,554,003 in machinery and office equipment and recognized $1,217,978 in net proceeds from the sale of the AVI building and the collection of receivables from the sale of VDL.

*Cash Flows from Financing Activities* 

Cash flows from financing activities primarily reflect proceeds from the sale of our securities.

During the nine months ended September 30, 2025, cash provided by financing activities was not significant.

During the nine months ended September 30, 2024, cash provided by financing activities included $83,556,563 in proceeds received in connection with the January and March PIPE Financings, net of issuance costs.

------

**Off-Balance Sheet Arrangements**

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

**<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk.</u>**

Not applicable.

**<u>Item 4. Controls and Procedures.</u>**

**Evaluation of disclosure controls and procedures.** We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily is required to apply its judgement in evaluating the cost-benefit relationship of possible controls and procedures.

We conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2025. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.

**Changes in internal controls.** Management determined there were no changes in internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II - OTHER INFORMATION**

**<u>Item 1. Legal Proceedings</u>**

For a description of material legal proceedings, see Note 7, "*General Litigation and Disputes*" to the accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

**<u>Item 1A. Risk Factors.</u>**

*There have been no material changes to the risk factors previously disclosed by us in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 20, 2025.*

**<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</u>**

None.

**<u>Item 3. Defaults Upon Senior Securities.</u>**

None.

**<u>Item 4. Mine Safety Disclosures.</u>**

Not applicable.

**<u>Item 5. Other Information.</u>**

*Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements*

On August 25, 2025, Chris Twitty, the Company's Chief Scientific Officer, adopted a Rule 10b5-1 trading plan. Dr. Twitty's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act ("Rule 10b5-1(c)") and provides for the potential sale of up to 154,832 shares of the Company's common stock subject to restricted stock units and stock options held by Dr. Twitty until December 31, 2026.

No other officers or directors, as defined in Rule 16a-1 (f) under the Exchange Act, adopted and/or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as defined in Regulation S-K Item 408, during the last fiscal quarter.

------

**<u>Item 6. Exhibits.</u>**

---

| | |
|:---|:---|
| 3.1 | <u>[Amended and Restated Articles of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 22, 2024)](https://www.sec.gov/Archives/edgar/data/1516551/000151655124000048/skye-ararticlesofincorpora.htm)</u> |
| 3.2 | <u>[Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 2, 2021)](https://www.sec.gov/Archives/edgar/data/0001516551/000164033421000483/skye_ex32.htm)</u> |
| 31.1 | <u>[Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934](skye-20250930xex311xsectio.htm)</u> |
| 31.2 | <u>[Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934](skye-20250930xex312xsectio.htm)</u> |
| 32.1\* | <u>[Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](skye-20250930xex321xsectio.htm)</u> |
| 32.2\* | <u>[Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](skye-20250930xex322xsectio.htm)</u> |
| 101 | The following materials from the Skye Biosciences, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Balance Sheets (Unaudited), (ii) Condensed Consolidated Statements of Operations (Unaudited), (iii) Condensed Consolidated Statements of Cash Flows (Unaudited), (iv) Condensed Consolidated Statements of Stockholders' Deficit (Unaudited), and (v) related Notes to the Unaudited Condensed Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

________

\*&nbsp;&nbsp;&nbsp;&nbsp;This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Skye Bioscience, Inc.,<br>a Nevada corporation** | **Skye Bioscience, Inc.,<br>a Nevada corporation** |
| November 10, 2025 | By: | */s/ Punit Dhillon* |
|  |  | *Punit Dhillon* |
|  | Its: | Chief Executive Officer, Secretary and Director<br>(Principal Executive Officer) |
| November 10, 2025 | By: | */s/ Kaitlyn Arsenault* |
|  |  | *Kaitlyn Arsenault* |
|  | Its: | Chief Financial Officer<br>(Principal Financial and Accounting Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**Certification of Principal Executive Officer, Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Punit Dhillon, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Skye Bioscience, Inc. for the quarter ended September 30, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| */s/ Punit Dhillon* |
| *Punit Dhillon* |
| Chief Executive Officer, Chairman of the Board, and Director |
| Date: November 10, 2025 |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**Certification of Principal Financial Officer, Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, *Kaitlyn Arsenault*, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Skye Bioscience, Inc. for the quarter ended September 30, 2025;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| */s/ Kaitlyn Arsenault* |
| *Kaitlyn Arsenault* |
| Chief Financial Officer |
| (Principal Accounting Officer) |
| Date: November 10, 2025 |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Skye Bioscience, Inc. a Nevada corporation (the "Company") on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Punit Dhillon, Chief Executive Officer, Chairman of the Board, and Director of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

---

| |
|:---|
| */s/ Punit Dhillon* |
| *Punit Dhillon* |
| Chief Executive Officer, Chairman of the Board, and Director |
| Date: November 10, 2025 |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Skye Bioscience, Inc. a Nevada corporation (the "Company") on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Kaitlyn Arsenault, Chief Financial Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

---

| |
|:---|
| */s/ Kaitlyn Arsenault* |
| *Kaitlyn Arsenault* |
| Chief Financial Officer |
| (Principal Accounting Officer) |
| Date: November 10, 2025 |

---

<br>